Psoriasis - Drug Pipeline Landscape, 2023

Psoriasis - Drug Pipeline Landscape, 2023

Psoriasis also known as psoriasis vulgaris, which is a chronic, proliferative and inflammatory autoimmune disease characterized by raised areas of abnormal skin as itchy, scaly and patchy. There are five main types of psoriasis - plaque, guttate, inverse, pustular and erythrodermic.

The cause of psoriasis is still unknown. A rare mutation in the gene encoding CARD14 along with environmental trigger causes plaque psoriasis. Chronic infections, stress, changes in the season and climate may worsen the condition. Psoriasis can occur by the microbes including S. aureus, C. albicans. Etc., At some times psoriasis can also occurs due to medicaments like beta blockers, antimalarials, TNF inhibitors, etc.,

Common signs and symptoms are inflamed skin covered with silvery white scaly skin. Bumps filled with non-infectious pus is formed. In severe cases, the plaques will grow. Bleeding occurs from the itchy and painful skin. Discoloration and detachment of fingernails and toenails from the nail bed occurs.

Psoriasis is diagnosed based on the skin appearance. No special blood tests or diagnostic procedures are required. Skin biopsy or scraping is performed.

Treatment for psoriasis is aimed to stop skin cells from growing quickly and to remove scales. Emollients are used to keep skin moisturized. Corticosteroids, synthetic vitamin D, retinoids and pimecrolimus cream and tacrolimus ointment are preferred. Phototherapy is also recommended which suppresses immune activity and reduce irritation.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve the treatment of psoriasis, such as bimekizumab, apremilast, AK101, and others. Key players involved in the development of therapies to treat psoriasis are Eli Lilly and Co., Johnson & Johnson, Amgen Inc., Bristol-Myers Squibb, and others. One drug is in late-stage development, 30+ drugs are in Phase III clinical trials, 40+ are in Phase II clinical trials, and some other drugs are in Phase I, preclinical, and discovery stages of development. In November 2022, UCB resubmitted the Biologics License Application (BLA) to the U.S. FDA for bimekizumab for the treatment of moderate to severe plaque psoriasis. In September 2022, Amgen announced the results of Phase III clinical trials of oral Otezla (apremilast).

Report Highlights

Global Insight Service's, Psoriasis - Drug Pipeline Landscape, 2023 report provides an overview of the Psoriasis pipeline drugs. This report covers detailed insights on Psoriasis drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Psoriasis pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.